BRPI0412127A - método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma - Google Patents

método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma

Info

Publication number
BRPI0412127A
BRPI0412127A BRPI0412127-9A BRPI0412127A BRPI0412127A BR PI0412127 A BRPI0412127 A BR PI0412127A BR PI0412127 A BRPI0412127 A BR PI0412127A BR PI0412127 A BRPI0412127 A BR PI0412127A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treating
pharmaceutically acceptable
symptom
compound
Prior art date
Application number
BRPI0412127-9A
Other languages
English (en)
Inventor
Scott W Grimm
Helen R Winter
Patricia C Davis
Raymond F Suckow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0412127A publication Critical patent/BRPI0412127A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO DE TRATAR PELO MENOS UM SINTOMA OU CONDIçãO, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USO DA MESMA". Um método de tratar ansiedade, agitação, hostilidade, pânico, distúrbios de comer, sintomas afetivos, sintomas do humor, sintomas negativos e positivos psicóticos, comumente associados com esquizofrenia, demência ansiedade, depressão, distúrbios do humor, distúrbios bipolares, mania bipolar, depressão bipolar, distúrbios cognitivos e distúrbios neurodegenerativos, compreendendo administrar uma quantidade eficaz da Fórmula (I) ou seu sal farmaceuticamente aceitável. Em outro aspecto da invenção, uma composição farmacêutica é provida, compreendendo uma quantidade eficaz da Fórmula (I) ou seu sal farmaceuticamente aceitável e pelo menos um veículo ou diluente farmaceuticamente aceitável.
BRPI0412127-9A 2003-07-02 2004-06-28 método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma BRPI0412127A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
PCT/GB2004/002783 WO2005002586A1 (en) 2003-07-02 2004-06-28 Metabolite of quetiapine

Publications (1)

Publication Number Publication Date
BRPI0412127A true BRPI0412127A (pt) 2006-08-15

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412127-9A BRPI0412127A (pt) 2003-07-02 2004-06-28 método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma

Country Status (20)

Country Link
US (1) US20050026900A1 (pt)
EP (1) EP1644005B1 (pt)
JP (1) JP2007516193A (pt)
KR (1) KR20060082037A (pt)
CN (1) CN1816339B (pt)
AR (1) AR045004A1 (pt)
AT (1) ATE477803T1 (pt)
AU (1) AU2004253334A1 (pt)
BR (1) BRPI0412127A (pt)
CA (1) CA2531284A1 (pt)
DE (1) DE602004028739D1 (pt)
ES (1) ES2349091T3 (pt)
IL (1) IL172616A0 (pt)
IS (1) IS8283A (pt)
MX (1) MXPA05013869A (pt)
NO (1) NO20060556L (pt)
RU (1) RU2005141060A (pt)
TW (1) TW200509944A (pt)
UY (1) UY28400A1 (pt)
WO (1) WO2005002586A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
NZ547911A (en) 2003-12-22 2010-06-25 Acadia Pharm Inc Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
EP1865962A2 (en) * 2005-04-04 2007-12-19 Arcadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
EP1869007A1 (en) * 2005-04-14 2007-12-26 Teva Pharmaceutical Industries Ltd Process for preparing quetiapine fumarate
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
JP2009516707A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 固形製剤
WO2007062339A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Liquid formulations
CN101360502B (zh) * 2005-11-18 2012-03-14 阿斯利康公司 结晶形式
WO2008116144A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Methods of treating mood disorders
CN101360724A (zh) * 2005-11-18 2009-02-04 阿斯利康公司 盐形式
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
JP2010531292A (ja) * 2006-12-20 2010-09-24 アストラゼネカ・アクチエボラーグ 化合物及びその使用
EP2120957A4 (en) * 2006-12-20 2011-05-04 Astrazeneca Ab COMPOUNDS AND USES THEREOF
EP2120563A4 (en) * 2006-12-20 2011-04-27 Astrazeneca Ab CONNECTIONS AND ITS USES
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US20110223207A1 (en) 2010-03-11 2011-09-15 Travis Mickle Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
AU5489299A (en) * 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用

Also Published As

Publication number Publication date
AU2004253334A1 (en) 2005-01-13
JP2007516193A (ja) 2007-06-21
UY28400A1 (es) 2005-01-31
ATE477803T1 (de) 2010-09-15
DE602004028739D1 (de) 2010-09-30
NO20060556L (no) 2006-04-03
CN1816339B (zh) 2010-12-15
WO2005002586A8 (en) 2006-02-09
RU2005141060A (ru) 2006-07-27
EP1644005B1 (en) 2010-08-18
ES2349091T3 (es) 2010-12-27
IS8283A (is) 2006-02-01
WO2005002586A1 (en) 2005-01-13
CN1816339A (zh) 2006-08-09
IL172616A0 (en) 2006-04-10
MXPA05013869A (es) 2006-02-28
CA2531284A1 (en) 2005-01-13
KR20060082037A (ko) 2006-07-14
TW200509944A (en) 2005-03-16
AR045004A1 (es) 2005-10-12
US20050026900A1 (en) 2005-02-03
EP1644005A1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
BRPI0412127A (pt) método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma
KR950700060A (ko) 운동 뉴우런 질병의 치료에 유용한 약품을 얻기 위한 2-아미노-6-트리플루오로메톡시 벤조티아졸(리루졸)의 사용(Application of 2-amino 6-trifluoromethoxy benzothiazole(riluzole) for obtaining a drug useful in the treatment of motor neuron diseases)
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
CY1111047T1 (el) Θεραπεια οφθαλμικων νεοαγγειακων διαταραχων οπως κηλιδωδους εκφυλισμου, αγγειοειδων γραμμωσεων, ραγοειδιτιδας και οιδηματος της ωχρης κηλιδας
BR9912866A (pt) Composto ou uma forma tautomérica, sal ousolvato farmaceuticamente aceitável do mesmo,composição farmacêutica, processo para otratamento ou a prevenção de uma doença, fatorde risco ou condição, mediada por hppar alfa e/ouhppar gama, e uso de um composto
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
BR9807132A (pt) Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2
GB9305623D0 (en) Therapeutic agents
BRPI0412262A (pt) derivados de azepina como agentes farmacêuticos
DE60206454D1 (de) Difluormethylen aromatische Ether und ihre Verwendung als Inhibitoren des Glycin-Typ-1-Transporters
BR0308796A (pt) Derivados de benzofurano
BRPI0512958A (pt) antagonistas de nk1
KR920016088A (ko) 하부 요로 질환의 치료
TWI340639B (en) Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph
BR9814042A (pt) "compostos de tiofeno condensados e seu uso farmacêutico"
EE200100478A (et) Vahend artriitilise haiguse raviks
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
EP1666064A4 (en) MEANS FOR THE TREATMENT OF DISEASES RELATED TO IMMUNOGLOBULIN GEN TRANSLATION
SE9902935D0 (sv) Pharmaceutical compositions
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
TW200507854A (en) Metabolite
DE68925173D1 (de) 4-Methyl und 4-Ethyl substituierte Pyrrolidin-2-one
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
KR910018028A (ko) 15- 데히드록시-16-옥소프로스타글란딘 화합물에 의한 생화학적 치료

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.